Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Risk
75% of CFOs Embrace Double Digit Spending Increases
CFOs want to spend more, but access to capital is the challenge, per the CFO Alliance sentiment report.
By
Adam Zaki
| January 26, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
Alex Gorsky
Financial Performance
J&J Gets Boost From Strong Cancer Drug Sales
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
By
Matthew Heller
| October 16, 2018
Read More
People
J&J’s Dominic Caruso to Step Down as CFO
The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.
By
Matthew Heller
| March 21, 2018
Read More
Human Capital & Careers
J&J, Aetna CEOs Hit Fee-for-Service System
The chief executives of two health-care giants want the industry to move further toward payments based on quality of care.
By
David Katz
| November 14, 2017
Read More
Financial Performance
J&J Posts $17.7B in Revenue, Misses Estimates
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
By
Matthew Heller
| April 19, 2017
Read More
Strategy
J&J Boosts Drug Roster With $30B Actelion Deal
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
By
Matthew Heller
| January 26, 2017
Read More
Strategy
J&J Sales Increase 1.7% But Miss Estimates
Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.
By
Matthew Heller
| January 24, 2017
Read More